Promise or peril? Impact of the Medicare drug benefit on the ESRD population.
Williams
Mark E
ME
Beth Israel Deconess Medical Centerand Harvard Medical School, Boston, MA, USA. mark.williams@joslin.harvard.edu
D003365:Costs and Cost Analysis; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy; D007342:Insurance Benefits / Q000191:economics; D019458:Insurance Coverage; D007356:Insurance, Pharmaceutical Services / Q000191:economics* / Q000331:legislation & jurisprudence; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000191:economics*; D006278:Medicare / Q000191:economics* / Q000331:legislation & jurisprudence; D014481:United States